Status:
COMPLETED
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Lead Sponsor:
Cumberland Pharmaceuticals
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Hyponatremia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients...
Eligibility Criteria
Inclusion
- Serum sodium levels 115 to \< 130mEq/L
- Euvolemic or Hypervolemic hyponatremia
Exclusion
- Clinical evidence of volume depletion or dehydration
- Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency
- Uncontrolled brady-or tachyarrhythmias requiring pacemaker placement or treatment
Key Trial Info
Start Date :
August 1 2000
Trial Type :
INTERVENTIONAL
End Date :
February 1 2003
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00380575
Start Date
August 1 2000
End Date
February 1 2003
Last Update
May 2 2014
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Mobile, Alabama, United States
2
Phoenix, Arizona, United States
3
Tuscon, Arizona, United States
4
La Jolla, California, United States